About Celera Pharma
Celera Pharma is a company based in India. Celera Pharma offers products and services including Nephrology Products and Cardiology Products.
- Headquarter India
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
- Legal Name Celera Pharma Pvt. Ltd
- Jurisdiction Tirumalagiri, Telangana, India
-
Annual Revenue
$2.13 M (USD)7.68as on Mar 31, 2024
-
Net Profit
$92.2 K (USD)44.04as on Mar 31, 2024
-
EBITDA
$132.18 K (USD)8.6as on Mar 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Celera Pharma
Celera Pharma offers a comprehensive portfolio of products and services, including Nephrology Products and Cardiology Products.
Nephrology formulations are marketed for essential healthcare needs.
Cardiology medicines are provided as part of the product range for patient care.
Funding Insights of Celera Pharma
Detailed funding history for Celera Pharma
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Celera Pharma
Investment portfolio details for Celera Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Celera Pharma
Detailed financials for Celera Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Celera Pharma Comparisons
Peer comparison for Celera Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Celera Pharma
Detailed competitors of Celera Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Celera Pharma
Complete news archive for Celera Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celera Pharma
Celera Pharma is headquartered in India.
Annual revenue of Celera Pharma is $2.13M as on Mar 31, 2024.
Celera Pharma is recognized as a leading biotechnology company that markets formulations across India, focusing on areas such as Nephrology, Cardiology, General Medicine, Urology, and Neurology. Quality medicines are delivered to enhance patient healthcare, with an emphasis on improving life quality through innovative offerings. The company is guided by principles of relentless growth via change management, empowerment of diverse abilities, and commitment to social responsibility for the common good. Continuous pursuit of excellence is maintained in its operations.
Celera Pharma offers Nephrology Products and Cardiology Products.